What is the Market's View on ATAI Life Sciences NV (ATAI) Stock's Price and Volume Trends Wednesday?

Overall market sentiment has been high on ATAI Life Sciences NV (ATAI) stock lately. ATAI receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

ATAI Life Sciences NV has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATAI!

See Full ATAI Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ATAI Stock Today?

ATAI Life Sciences NV (ATAI) stock is lower by -2.19% while the S&P 500 is higher by 0.27% as of 10:27 AM on Wednesday, Nov 29. ATAI is down -$0.02 from the previous closing price of $1.14 on volume of 308,405 shares. Over the past year the S&P 500 has risen 15.21% while ATAI is down -62.79%. ATAI lost -$0.46 per share in the over the last 12 months.

More About ATAI Life Sciences NV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. Click Here to get the full Stock Report for ATAI Life Sciences NV stock.